Field F J, Albright E, Mathur S N
Metabolism. 1986 Dec;35(12):1085-9. doi: 10.1016/0026-0495(86)90019-3.
Hepatic and intestinal cholesterol metabolism were investigated in the hypothyroid and thyroxine-treated hypothyroid rat. Plasma cholesterol levels were significantly increased in hypothyroid animals. After thyroxine administration, plasma cholesterol levels were reduced to levels observed in euthyroid controls. Hypothyroidism caused a significant decrease in biliary cholesterol output, which was reversed with thyroxine treatment. In contrast, biliary bile acid output was unchanged by the thyroid status. Cholesterol synthesis, as estimated by HMG-CoA reductase activity, was decreased in the liver of hypothyroid animals. Thyroxine administration, however, significantly increased reductase activity returning it to control levels. Hypothyroidism did not affect HMG-CoA reductase activity in the intestine, but thyroxine administration markedly stimulated the activity of this enzyme in this organ. Cholesterol esterification, as estimated by ACAT activity, was decreased in the liver of hypothyroid rats, while intestinal ACAT activity was greatly increased. Thyroxine treatment reversed these effects of hypothyroidism on ACAT activity in both organs. An increase in microsomal cholesterol content in the intestine of hypothyroid rats was associated with the observed increase in intestinal ACAT activity. The percent of cholesterol that was absorbed in the intestine was not changed by the thyroid status of the animal. The data suggest that the changes observed in cholesterol metabolism in hypothyroid rats or hypothyroid rats treated with thyroxine for 1 week cannot account for the increase in plasma cholesterol levels observed in the hypothyroid rat. This implies that other factors that were not studied, such as changes in lipoprotein catabolism, are likely to contribute to the hypercholesterolemia of hypothyroidism.
在甲状腺功能减退和甲状腺素治疗的甲状腺功能减退大鼠中研究了肝脏和肠道的胆固醇代谢。甲状腺功能减退的动物血浆胆固醇水平显著升高。给予甲状腺素后,血浆胆固醇水平降至正常甲状腺对照组观察到的水平。甲状腺功能减退导致胆汁胆固醇输出显著减少,甲状腺素治疗可使其逆转。相反,胆汁酸输出不受甲状腺状态影响。通过HMG-CoA还原酶活性估计,甲状腺功能减退动物肝脏中的胆固醇合成减少。然而,给予甲状腺素显著增加了还原酶活性,使其恢复到对照水平。甲状腺功能减退不影响肠道中的HMG-CoA还原酶活性,但给予甲状腺素显著刺激了该器官中该酶的活性。通过ACAT活性估计,甲状腺功能减退大鼠肝脏中的胆固醇酯化减少,而肠道ACAT活性大大增加。甲状腺素治疗逆转了甲状腺功能减退对两个器官中ACAT活性的这些影响。甲状腺功能减退大鼠肠道中微粒体胆固醇含量的增加与观察到的肠道ACAT活性增加有关。动物的甲状腺状态不改变肠道中吸收的胆固醇百分比。数据表明,甲状腺功能减退大鼠或用甲状腺素治疗1周的甲状腺功能减退大鼠中观察到的胆固醇代谢变化不能解释甲状腺功能减退大鼠中观察到的血浆胆固醇水平升高。这意味着未研究的其他因素,如脂蛋白分解代谢的变化,可能导致甲状腺功能减退的高胆固醇血症。